|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Patients with both CCAD and diffuse sinonasal polyps had an allergy prevalence approaching that of CCAD and an asthma prevalence approaching CRSwNP NOS.
|
31600866 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
VDR KO did not alter Nos2 mRNA levels but significantly increased Arg1 mRNA levels in tumor M-MDSC by 100 %.
|
31783150 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In summary, the location and type of Nos2<sup>high</sup> cells, NO flux, and the inflammatory status of other cells, such as Cox2<sup>high</sup> cells in the tumor niche contribute to Nos2 inflammatory mechanisms that promote disease progression of 4T1 tumors.
|
31683257 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This finding was accompanied with upregulated pro-inflammatory factors IL-6, TNFα, COX2 and NOS2 in tumors of Par2<sup>-/-</sup> mice.
|
31733286 |
2020 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphisms of NOS2 and MAFK are associated with ATDILI susceptibility in Chinese patients with tuberculosis.
|
31742742 |
2020 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD5+ diffuse large B-cell lymphoma (DLBCL), NOS represents a distinct subset of DLBCL associated with poorer outcomes and extranodal disease.
|
31533521 |
2020 |
|
Tumor Progression
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Using a triple negative murine breast cancer model, we explored the potential role of macrophage Nos2 on 4T1 tumor progression.
|
31683257 |
2020 |
|
Acute pancreatitis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
S-adenosylmethionine administration enhanced Nos2 mRNA expression and cystathionine β-synthase nitration and triggered homocysteine accumulation in acute pancreatitis.
|
31539805 |
2020 |
|
Burkitt Lymphoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
A subset of HGBCL, NOS displayed recurrent alterations of Burkitt lymphoma related genes such as MYC, ID3 and DDX3X and homozygous deletions of 9p21/CDKN2A whereas other cases were genetically closer to GCB-DLBCL.
|
31738823 |
2020 |
|
Adult Burkitt Lymphoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
A subset of HGBCL, NOS displayed recurrent alterations of Burkitt lymphoma related genes such as MYC, ID3 and DDX3X and homozygous deletions of 9p21/CDKN2A whereas other cases were genetically closer to GCB-DLBCL.
|
31738823 |
2020 |
|
Childhood Burkitt Lymphoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
A subset of HGBCL, NOS displayed recurrent alterations of Burkitt lymphoma related genes such as MYC, ID3 and DDX3X and homozygous deletions of 9p21/CDKN2A whereas other cases were genetically closer to GCB-DLBCL.
|
31738823 |
2020 |
|
T-cell/histiocyte rich large B-cell lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
CD40, CD50, and CD54 were overexpressed in THRLBCL relative to DLBCL, NOS, perhaps contributing to the predominance of T cells in THRLBCL.
|
31254446 |
2020 |
|
Disorder of Achilles tendon
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The rs2779249 CA genotype within the human iNOS gene appears to protect individuals from Achilles tendinopathy.
|
31761559 |
2020 |
|
Hemorrhoids
|
0.010 |
Biomarker
|
disease |
BEFREE |
The number of haemorrhoid specimens showing positive immunoreactivity of NOS in the vascular endothelium was significantly higher than that in rectal tissue for NOS1 (11/14 (79%) vs 1/6 (17%); p=0.018) and NOS3 (8/14 (57%) vs 0/6 (0%); p=0.042), but not for NOS2 (6/14 (43%) vs 4/6 (67%); p=0.63).
|
30058493 |
2020 |
|
Absence of sensation
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We have used iontophoresis in vivo to study the effect of the NOS inhibitor L-NAME (L-NG-Nitroarginine methyl ester) and the NO donors SIN-1 (3-Morpholinosydnonimine hydrochloride) and SNOG (S-Nitrosoglutathione) on VCN units under urethane anaesthesia.
|
31494975 |
2020 |
|
Aspirin exacerbated respiratory disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Prevalence of allergy was significantly higher in AFRS (100%), CCAD (97.6%), CRSwNP/CC (84.6%), and AERD (82.6%) when compared with CRSwNP NOS (56.1%) (p < 0.001).
|
31600866 |
2020 |
|
Asthma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Immunostaining revealed expression of iNOS proteins mainly in epithelial cells in the airways, while it was mainly expressed in macrophages in the alveolar region in the snBA group.
|
30667100 |
2019 |
|
Sepsis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In vivo investigation showed that γ-GC reduced sepsis lethality and attenuated systemic inflammatory responses in mice, as well as inhibited lipopolysaccharide (LPS)-stimulated production of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), high-mobility group box 1 (HMGB1), and nitric oxide (NO) and the expression of inducible NO synthase and cyclooxygenase 2 in RAW264.7 cells.
|
30326393 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.570 |
AlteredExpression
|
disease |
BEFREE |
Here we studied the possible role of these gasotransmitters in both murine and human type 2 diabetes (T2D) by mapping the expression pattern of neural nitric oxide synthase (nNOS), inducible NOS (iNOS), constitutive heme oxygenase (HO-2), and inducible HO (HO-1) in isolated pancreatic islets.
|
31607476 |
2019 |
|
Endotoxemia
|
0.540 |
AlteredExpression
|
phenotype |
BEFREE |
Consumption of a HFD for 14 weeks caused intestinal permeabilization and endotoxemia, which were associated with a decreased ileum expression of tight junction (TJ) proteins (occludin, ZO-1 and claudin-1), increased expression of NADPH oxidase (NOX1 and NOX4) and NOS2 and oxidative stress, and activation of redox sensitive signals (NF-κB and ERK1/2) that regulate TJ dynamics.
|
31330482 |
2019 |
|
Endotoxemia
|
0.540 |
Biomarker
|
phenotype |
BEFREE |
Experimental endotoxemia <i>in vivo</i> or <i>in vitro</i> induced iNOS protein and mtROS production.
|
31772705 |
2019 |
|
Septicemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In vivo investigation showed that γ-GC reduced sepsis lethality and attenuated systemic inflammatory responses in mice, as well as inhibited lipopolysaccharide (LPS)-stimulated production of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), high-mobility group box 1 (HMGB1), and nitric oxide (NO) and the expression of inducible NO synthase and cyclooxygenase 2 in RAW264.7 cells.
|
30326393 |
2019 |
|
Seizures
|
0.320 |
Biomarker
|
phenotype |
BEFREE |
Then followed by co-injection of its sub-effective dose and NOS inhibitors including 7-Nitroindazole (7-NI), aminoguanidine (AG) and L-N<sup>G</sup>-Nitroarginine methyl ester (L-NAME) to evaluate the changes in seizure threshold and the possible involvement of nitrergic system.
|
31202800 |
2019 |
|
Ureteral obstruction
|
0.320 |
Biomarker
|
phenotype |
BEFREE |
In addition, macrophage infiltration, up-regulation of M1 (NOS2) and M2 (CD206) macrophage markers, and up-regulation of pro-inflammatory molecules (tumour necrosis factor, CCL2, interleukin-36α) in WT UUO kidney were unchanged in Par2-/- UUO.
|
31314137 |
2019 |
|
Hypoxic-Ischemic Encephalopathy
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
The haplotype (CCTTT)<sub>14</sub>/TT, formed by the expansion of the - 2.5 kb (CCTTT)<sub>n</sub> microsatellite in the NOS2A gene promoter and the -511 C➝ T SNP of the IL-1β gene promoter, might be a useful marker to identify patients who are at high risk for developing CP after hypoxic-ischemic encephalopathy.
|
29931509 |
2019 |